Medicina
Fakultatea
Iuliu Hațieganu University of Medicine and Pharmacy
Cluj, RumaníaIuliu Hațieganu University of Medicine and Pharmacy-ko ikertzaileekin lankidetzan egindako argitalpenak (59)
2024
-
Clinician treatment choices for post-traumatic stress disorder: ambassadors survey of psychiatrists in 39 European countries
European Psychiatry, Vol. 67, Núm. 1
-
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97
-
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 2
2023
-
Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode
Liver International, Vol. 43, Núm. 7, pp. 1548-1557
-
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products
Clinical and experimental rheumatology, Vol. 41, Núm. 3, pp. 543-553
-
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 204-222
-
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
-
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
European Journal of Cancer, Vol. 183, pp. 174-187
-
Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212
-
Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding
Gut, Vol. 72, Núm. 4, pp. 749-758
-
Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome
Transplantation, Vol. 107, Núm. 6, pp. 1330-1340
-
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185
-
Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis
Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062
-
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
ESMO Open, Vol. 8, Núm. 6
-
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92
-
Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct
Pathology Research and Practice, Vol. 247
-
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069
2022
-
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
European Urology, Vol. 82, Núm. 3, pp. 283-292
-
Clinical decision-making style preferences of European psychiatrists: Results from the Ambassadors survey in 38 countries
European Psychiatry, Vol. 65, Núm. 1
-
Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease
Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2276-2286.e6